HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

COSM

Cosmos Health Inc. (NASDAQ)

Healthcare — Medical Distribution

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.

None 1 analysts
$0.20
+$0.02 (+9.19%)
Target: $4.50 (2127.7%)
Sign in to add COSM to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$12.52M
P/E Ratio (TTM)-
Forward P/E2.88
EPS (TTM)$-0.66
Dividend Yield-
Profit Margin-30.41%
Revenue Growth30.70%
ROE-92.32%
Debt/Equity87.87
Recommendation None
Analyst Target$4.50
Analysts1
Indexes NASDAQ

Technical Indicators

RSI (14)42.5
Beta4.12
SMA 20-
SMA 40-
52-Week High$1.32
52-Week Low$0.16
50-Day Avg$0.28
200-Day Avg$0.52
Avg Volume$6.47M
Volume$11.15M

Performance Analysis

NEUTRAL

COSM presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($0.16), which could present a value opportunity.
~ RSI at 42.5 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
+ Strong revenue growth of 30.7% year-over-year.
- Operating at a loss with -30.4% margin.
~ Wall Street consensus is "none" from 1 analysts.
+ Average analyst target of $4.50 implies 2127.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:04 UTC

Back to Screener Export Report